---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-004526"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:17:47.684342+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical reports FY2024 net loss of $12.2M; cash at $9.1M; oncology trial approved

## Summary
- Net loss of $12.2M for FY ended March 31, 2024, compared to $12.0M in FY2023.
- Cash balance of $5.4M at March 31, 2024, increased to $9.1M as of June 25, 2024.
- Received HREC ethics approval for Hemopurifier safety/feasibility oncology trial in Australia, valid through 2027.
- FDA approved internal manufacturing facility in April 2024.
- COVID-19 trial in India remains open with one patient treated; monitoring H5N1 avian flu situation.

## SEC filing metadata
- accession: 0001683168-24-004526
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316824004526/0001683168-24-004526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316824004526/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-004526
- JSON: https://secwatch.observer/filing/0001683168-24-004526.json
- Plain text: https://secwatch.observer/filing/0001683168-24-004526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.